FierceBiotech

Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate ...

<0> Teva Pharmaceutical Industries Ltd.IR:United States 215-591-8912or215-591-3033orIsrael 972 (3) 926-7656orPR:Israel 972 (3) 926-7687orUnited States 215-591-8974or215-284-0213 </0> Teva ...
Business Wire

Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes

AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and ...
Healthline

Side Effects of Copaxone: What You Need to Know

Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
FiercePharma

“10 Years & Counting” Celebrates a Decade of National Team COPAXONE® Achievements

Teva Neuroscience launches a year-long anniversary celebration including a quest to find the next Team member Team COPAXONE ® is a group of 10 individuals living with an MS diagnosis who have chosen ...
FierceBiotech

COPAXONE® 15-YEAR STUDY IN MULTIPLE SCLEROSIS PATIENTS DEMONSTRATES ROBUST LONG-TERM EFFICACY AND SAFETY

- More than 80 percent of patients were able to walk unassisted following 15 years of treatment and average disease duration of 22 years - The majority of patients experienced either stable or ...